Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4056 - Long non-coding RNAs are differentially expressed between bladder cancer subtypes.


10 Sep 2017


Poster display session


Sébastien Rinaldetti


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


S. Rinaldetti1, E. Rempel2, T.S. Worst3, M. Eckstein4, A. Steidler3, C.A. Weiss5, C. Bolenz6, A. Hartmann7, P. Erben3

Author affiliations

  • 1 Department Of Oncology And Hematology, Medical Faculty Mannheim, Heidelberg University, 68167 - Mannheim/DE
  • 2 Division Of Signaling And Functional Genomics, Heidelberg University, Heidelberg/DE
  • 3 Department Of Urology, Medical Faculty Mannheim, Heidelberg University, Mannheim/DE
  • 4 Institute Of Pathology, University Erlangen-Nuremberg, Erlangen/DE
  • 5 Institute Of Pathology, Medical Faculty Mannheim, Heidelberg University, Mannheim/DE
  • 6 Department Of Urology, University of Ulm, Ulm/DE
  • 7 Department Of Pathology, University Erlangen, Erlangen/DE


Abstract 4056


The recent identification of molecular bladder cancer subtypes by whole transcriptome studies showed similarities to molecular breast cancer phenotypes. We here validate these subtypes with a sensitive 36 gene nCounter screening and analyse relevant lncRNA for their differential expression.


RNA has been extracted from chemotherapy-naïve muscle-invasive bladder cancer (MIBC) after radical cystectomy (follow-up: 12 years, n = 48). A multiple marker gene panel has been quantified with the nCounter technology. In silico validation of the classifier geneset on 170 MIBCs has been performed. All squamous carcinoma were excluded. LncRNAs were analyzed in a clustering-independent assessment. Multivariate analyses were performed by a Cox proportional hazards model.


36 consensus genes were generated by Venn diagrams based on the Mannheim, Lund, Chungbuk and MDA cohorts. This minimal set of genes generated 3 stable clusters: basal, luminal and infiltrated. The subtype specific assessment of 14 lncRNAs relevant in bladder cancer showed a highly subtype specific expression for 9 lncRNAs. The infiltrated subtype, characterized by an activated p53 downstream signature, showed an overexpression of SRA1 and MEG3 (p ≤ 0.003) - the latter is known for promoting the expression of TP53. The lncRNAs H19, GAS5, TUG1 and CBR3-AS1 showed a significant upregulation in the luminal subtype (p 


In this study, MIBC subtypes have been validated by a sensitive quantification method. Molecular subtypes and H19 prove to be independent risk factors superior to TNM. This study demonstrates for the first time a differential expression of lncRNA between MIBC subtypes. The potential impact of lncRNA on phenotype determination has to be investigated in vivo.

Clinical trial identification

Legal entity responsible for the study

BRIDGE Consortium




R. Sébastien: Novartis Research Fund. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.